Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer Read more
WuXi STA First CDMO to Support the Approval of an Innovative Drug in China Through the “MAH” Pilot Read more